Hepatitis C

Pegasys marketing authorization granted by European Commission

Published in Vaccine Weekly, July 24th, 2002

Roche announced that Pegasys (peginterferon alfa 2-a (40 kDa)), a new generation pegylated interferon for the treatment of hepatitis C, has been granted marketing authorization by the European Commission.

The decision was based on the unanimous positive opinion adopted by the Committee for Proprietary Medicinal Products on March 21, 2002.

This license allows millions of hepatitis C patients in the European Union to access a treatment with increased efficacy, even for those with the more difficult-to-treat forms of the disease.

"Today is a very important day for Roche and for Pegasys," said William M. Burns, head of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-07-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry